Who is sponsoring NCT04219176?

NCT04219176 is sponsored by Université de Sousse.

What drugs are being tested in NCT04219176?

Interventions in NCT04219176: Spectral optical coherence tomography.

What condition does NCT04219176 study?

NCT04219176 studies Ocular Toxoplasmosis.

Is NCT04219176 still recruiting?

NCT04219176 is currently completed. Last updated 27 January 2020.

Last reviewed 2020-01-27 · How we verify

NCT04219176

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Spectral Optical Coherence Tomography Findings in Patients With Ocular Toxoplasmosis

Completed Last updated 27 January 2020

What this trial tests

trial testing Spectral optical coherence tomography in Ocular Toxoplasmosis in 9 participants. Completed in 2 January 2018.

Timeline

23 January 2002

Primary endpoint
29 March 2017

2 January 2018

Quick facts

Lead sponsor	Université de Sousse
Status	Completed
Study type	OBSERVATIONAL
Enrollment	9
Start date	23 January 2002
Primary completion	29 March 2017
Estimated completion	2 January 2018

Drugs / interventions tested

Spectral optical coherence tomography

Conditions studied

Ocular Toxoplasmosis — all drugs for Ocular Toxoplasmosis →

Sponsor

Université de Sousse

Who can join

Eligibility, any sex, with Ocular Toxoplasmosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ocular toxoplasmosis is the most common cause of infectious uveitis worldwide. The diagnosis of ocular toxoplasmosis is primarily clinical when it is a typical presentation .With an atypical presentation in the fundus, parasitological diagnosis is a decisive contribution, as well as multimodal imaging. We investigate on vitreal, retinal, and choroidal morphologic changes in active and scarred toxoplasmosis lesions using swept source optical coherence tomography.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Spectral optical coherence tomography findings in patients with ocular toxoplasmosis: A case series study.
Ammar F, Mahjoub A, Ben Abdesslam N, Knani L, et al · · 2020 · cited 4× · PMID 32435471 · DOI 10.1016/j.amsu.2020.04.008

Verify or expand the search:

Other Université de Sousse trials

Trials by the same sponsor.

NCT04798937 — Motivational Interviewing to Improve Self Management in Youth With Type 1 Diabetes · NA · completed
NCT04649970 — Antegrade Double-J Stent Placement for the Treatment of Malignant Obstructive Uropathy · completed
NCT04843670 — Isolated Pancreatic Loop With Modified Pancreaticojejunostomy · completed
NCT04709718 — Surgical Management of Giant Hepatic Hemangioma · completed
NCT04988958 — Radical Versus Conservative Surgical Treatment of Liver Hydatid Cysts · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04219176 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Université de Sousse
Last refreshed: 27 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04219176.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing